How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
0 citations0 with PMIDValidation: 0%0 supporting / 0 opposing
✓For(0)
No supporting evidence
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
No evidence recorded in matrix format.
Legacy Card View — expandable citation cards
✓ Supporting Evidence
0
No evidence recorded
✗ Opposing Evidence
0
No evidence recorded
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
No linked debates yet. This hypothesis will accumulate debate perspectives as it is discussed in future analysis sessions.
Price History
7d Trend
↘
Falling
7d Momentum
▼ 32.3%
Volatility
Low
0.0097
Events (7d)
6
Clinical Trials (0)
No clinical trials data available
📚 Cited Papers (0)
No linked papers yet
📅 Citation Freshness Audit
Freshness score = exp(-age×ln2/5): halves every 5 years.
Green >0.6,
Amber 0.3–0.6,
Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
💬 Discussion
Loading comments...
No DepMap CRISPR Chronos data found for this gene.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
Loading history…
⚖️ Governance History
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions,
Elo penalties, or pause grants affect this subject.
IF participants receive the experimental intervention versus control, THEN the primary outcome measure will show a statistically significant difference in the expected direction within 12 weeks.
pendingconf: 0.50
Expected outcome: Effect size of at least 0.5 standard deviations between intervention and control groups on the primary measurable endpoint
Falsified by: No statistically significant difference between groups (p > 0.05) or effect size < 0.3 SD after 12 weeks of intervention
Method: Randomized controlled trial with parallel groups using a placebo or standard-of-care control arm in a human cohort (n=200, 1:1 allocation)
IF the biomarker levels are measured and stratified by disease severity, THEN a monotonic increase or decrease in biomarker concentration will be observed across severity groups within the cross-sectional assessment.
pendingconf: 0.50
Expected outcome: Linear trend in biomarker levels across severity tiers with Spearman correlation coefficient > 0.4
Falsified by: No significant trend observed (Spearman ρ < 0.2) or non-monotonic pattern inconsistent with hypothesis direction
Method: Cross-sectional cohort study using patient registry data from electronic health records or biobank samples (n=500 stratified by severity)